1.Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
Domenico De BERARDIS ; Gabriella RAPINI ; Luigi OLIVIERI ; Agostina GIARDINI ; Ida De LAURETIS ; Nicola SERRONI ; Laura ORSOLINI ; Michele FORNARO ; Felice IASEVOLI ; Sabatino TROTTA ; Paolo COTTURA ; Federica VELLANTE ; Marco ALESSANDRINI ; Massimo Di GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2021;19(1):174-178
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2 /D3 receptors with preferential binding to the D 3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.